论文部分内容阅读
目的观察新辅助化疗联合腹腔镜手术治疗低位直肠癌的效果。方法将240例低位直肠癌患者随机分为试验组和对照组各120例。2组患者均行腹腔镜下直肠癌根治术,试验组额外给予FOLFOX4方案新辅助化疗。治疗后比较2组患者保肛率、复发率、生存率、疗效和不良反应发生率。结果试验组治疗后保肛率、生存率和总有效率高于对照组,差异均有统计学意义(P<0.05)。2组复发率和不良反应发生率差异均无统计学意义(P>0.05)。结论新辅助化疗联合腹腔镜手术治疗低位直肠癌具有较高的保肛率、生存率和疗效,同时不增加复发率和不良反应发生率,值得临床推广应用。
Objective To observe the effect of neoadjuvant chemotherapy combined with laparoscopic surgery on low rectal cancer. Methods 240 patients with low rectal cancer were randomly divided into experimental group and control group of 120 cases. Both groups underwent laparoscopic radical resection of rectal cancer. The experimental group was additionally given FOLFOX4 regimen neoadjuvant chemotherapy. After treatment, the anal sphincter rate, recurrence rate, survival rate, curative effect and incidence of adverse reactions were compared between the two groups. Results After treatment, the anal sphincter preservation rate, survival rate and total effective rate in the experimental group were significantly higher than those in the control group (P <0.05). There was no significant difference in the recurrence rate and incidence of adverse reactions between the two groups (P> 0.05). Conclusion Neoadjuvant chemotherapy combined with laparoscopic surgery for rectal cancer has a high anal rectal rate, survival rate and efficacy, while not increasing the recurrence rate and incidence of adverse reactions, worthy of clinical application.